Welcome to our dedicated page for Leap Therapeutic news (Ticker: LPTX), a resource for investors and traders seeking the latest updates and insights on Leap Therapeutic stock.
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a clinical-stage biopharmaceutical company advancing targeted therapies for challenging cancers. This page provides investors and researchers with direct access to official announcements and verified updates about the company’s oncology programs.
Key resources include: Clinical trial progress for lead candidate DKN-01 (targeting DKK1), developments in FL-301 (Claudin18.2 program), partnership announcements, and financial disclosures. All content is sourced from authorized releases to ensure reliability.
Users benefit from: Timely updates on regulatory milestones, research collaborations, and pipeline advancements in gastrointestinal/gastroesophageal cancers. Content is organized chronologically for efficient tracking of material events.
Bookmark this page to monitor Leap Therapeutics’ progress in developing precision antibody therapies, with new updates added as official announcements become available.
Leap Therapeutics (Nasdaq:LPTX) presented final Part B results from the Phase 2 DeFianCe study of sirexatamab (DKN-01) plus bevacizumab and chemotherapy vs bevacizumab and chemotherapy in previously treated MSS colorectal cancer at ESMO 2025.
In the DKK1-high populations, sirexatamab improved response and survival: upper-median (n=88) ORR 38.0% vs 23.7%, mPFS 9.03 vs 7.06 months (HR 0.61, p=0.0255), mOS not reached vs 14.39 months (HR 0.42, p=0.0118); upper-quartile (n=44) ORR 44.0% vs 15.8%, mPFS 9.36 vs 5.88 months (HR 0.46, p=0.0168), mOS not reached vs 9.66 months (HR 0.17, p<0.001).
In the full ITT population (n=188) ORR was 35.1% vs 26.6% and mPFS 9.2 vs 8.3 months (HR 0.84, p=0.1712). Safety was reported as similar between arms. Leap plans regulatory engagement and biomarker optimization.
Leap Therapeutics (Nasdaq:LPTX) closed a private placement led by Winklevoss Capital raising $58,888,888 in cash to initiate a digital asset treasury strategy. At closing Leap issued 15,212,311 shares, pre-funded warrants for 80,768,504 shares, and warrants for 71,985,605 shares with an exercise price of $0.5335. Winklevoss Capital will provide capital and strategic support and has rights to nominate two board members, one to serve as board chair. A registration rights agreement obligates Leap to file a resale registration statement with the SEC. A portion of proceeds will fund development of FL-501 and sirexatamab.
Leap Therapeutics (Nasdaq:LPTX) announced a $58,888,888 PIPE led by Winklevoss Capital to initiate a digital asset treasury strategy. The transaction includes 95,849,353 purchased shares or pre-funded warrants and 71,887,008 warrants exercisable at $0.5335 per share, implying an aggregate exercise price per Unit of $0.61439. Winklevoss Capital will provide capital and strategic support and has the right to nominate two board members, including the board chair, as Leap expands its board to 12 members. A portion of proceeds will fund therapeutic programs including FL-501 and sirexatamab. Closing expected on or about October 8, 2025, subject to customary conditions.
Leap Therapeutics (NASDAQ:LPTX) announced it will present final clinical results from Part B of the DeFianCe Phase 2 study at the ESMO Congress 2025. The study evaluates sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, combined with bevacizumab and chemotherapy versus a control arm in advanced microsatellite stable (MSS) colorectal cancer patients.
The presentation will be delivered by Dr. Zev A. Wainberg from UCLA in a Mini Oral Session on October 19, 2025 at 4:05 p.m. CEST in Berlin, Germany. The study focuses on second-line therapy for MSS colorectal cancer patients who have received one prior systemic therapy.
Leap Therapeutics (NASDAQ:LPTX) reported Q2 2025 financial results, highlighting significant strategic changes and clinical developments. The company announced a 75% workforce reduction and initiated exploration of strategic alternatives to maximize shareholder value, engaging Raymond James as financial advisor.
Financial results showed a net loss of $16.6 million, improved from $20.4 million in Q2 2024. Research and development expenses decreased to $10.5 million from $17.9 million year-over-year. The company reported $18.1 million in cash as of June 30, 2025.
Clinical updates included positive data from the Phase 2 DeFianCe study of sirexatamab in colorectal cancer, showing statistically significant benefits in specific patient populations. Restructuring costs, primarily for severance, are estimated at $4.5 million.
Leap Therapeutics (NASDAQ:LPTX) announced preclinical data presentation for FL-501, their novel GDF-15 neutralizing antibody, at the AACR 2025 Annual Meeting in Chicago. FL-501 shows promise in treating cancer cachexia, a life-threatening condition characterized by weight loss and muscle wasting.
Key findings demonstrate that FL-501 exhibited a 2-3-fold longer half-life and 50% reduced clearance compared to its wild-type precursor and ponsegromab in humanized FcRn mouse studies. The antibody successfully restored body composition in mouse cachexia models and effectively countered cisplatin-induced weight loss in non-small cell lung cancer patient-derived xenograft models.
The company plans to advance FL-501 into clinical trials in 2026, positioning it as a potential best-in-class treatment option for cancer cachexia, a condition currently lacking effective treatments.
Leap Therapeutics (LPTX) has announced a virtual Key Opinion Leader (KOL) event scheduled for April 23, 2025, at 2:30 p.m. ET to discuss their lead drug candidate sirexatamab (DKN-01) in treating second-line patients with advanced microsatellite stable colorectal cancer.
The event will feature Dr. Zev A. Wainberg, Professor of Medicine at UCLA and co-director of the UCLA GI Oncology Program, who will join Leap's Chief Medical Officer, Dr. Cynthia Sirard, to discuss the unmet needs in colorectal cancer treatment. They will review positive data from Part B of the Phase 2 DeFianCe study of sirexatamab, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein.
The presentation will be followed by a live Q&A session, with a replay available on the company's investor relations website.
Leap Therapeutics (LPTX) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its clinical trials. The company's Phase 2 DeFianCe study of sirexatamab showed promising results in colorectal cancer treatment, with a 32% higher overall response rate and 3.5-month longer progression-free survival in patients with high DKK1 levels.
Financial results show a net loss of $67.6 million for 2024, improved from $81.4 million in 2023. Research and development expenses decreased to $57.2 million from $73.2 million, while general and administrative expenses reduced to $12.8 million from $13.8 million. The company maintains $47.2 million in cash as of December 31, 2024.
The company sees a significant market opportunity, with approximately 30,000 second-line CRC patients in the US and 160,000 in the next 7 largest markets. Leap has engaged a financial advisor to explore business development opportunities for sirexatamab.
FAQ
What is the current stock price of Leap Therapeutic (LPTX)?
What is the market cap of Leap Therapeutic (LPTX)?
